Fig. 4: Quadrivalent mosaic SARS-CoV-2 nanoparticle vaccine-elicited potent and broad neutralization antibody responses in cynomolgus macaques against pseudoviruses with various mutations in the RBD of SARS-CoV-2. | Nature Communications

Fig. 4: Quadrivalent mosaic SARS-CoV-2 nanoparticle vaccine-elicited potent and broad neutralization antibody responses in cynomolgus macaques against pseudoviruses with various mutations in the RBD of SARS-CoV-2.

From: Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants

Fig. 4

a RBD key residue substitutions that affect the neutralizing sensitivity of ancestral and variant SARS-CoV-2 isolates are colored. The RBD residue mutations of circulating SARS-CoV-2 variants were downloaded from the Global initiative on sharing all influenza data (GISAID) EpiCoV database. RBD receptor-binding domain, VOC Variant of Concern, VOI Variant of Interest, VUM Variants Under Monitoring. b Neutralization antibody titers of HexaPro-based SARS-CoV-2 nanoparticle vaccine-elicited sera 2 weeks after the second booster dose (n = 4 cynomolgus macaques in each group) against a panel of SARS-CoV-2 mutant pseudoviruses. The neutralization titers were expressed as log10 (means ± SD). The pseudoviruses neutralization titers were present as a heatmap colored in red-to-green gradient. A deeper red represents a higher pseudovirus neutralization activity, and a deeper green a lower pseudovirus neutralization activity. c BLI binding competition analysis with the hACE2 receptor of serum samples at peak potency collected from cynomolgus macaques that were vaccinated with HexaPro-based nanoparticle vaccines. Source data are provided as a Source Data file.

Back to article page